Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE i study

Gastroenterology

Volumn 143, Issue 5, 2012, Pages

  Sandborn, William J ^a   Travis, Simon ^b   Moro, Luigi ^c   Jones, Richard ^c   Gautille, Theres ^d   Bagin, Robert ^d   Huang, Michael ^d   Yeung, Phil ^d   Ballard, E David ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c Cosmo Pharmaceuticals SpA ^*  (Italy)

^d Santarus Inc   (United States)

Author keywords

Clinical Trial Result; Colon; Inflammation; Inflammatory Bowel Disease

Indexed keywords

BUDESONIDE; MESALAZINE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; BACKACHE; COLONOSCOPY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RELEASE; FEMALE; FEVER; FLATULENCE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; ULCERATIVE COLITIS;

EID: 84868127664     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.08.003     Document Type: Article

References (35)

1. I. Ordas, L. Eckmann, M. Talamini Ulcerative colitis Lancet 2012 Aug 17 [Epub ahead of print]
2. S.C. Truelove, L.J. Witts Cortisone in ulcerative colitis Final report on a therapeutic trial BMJ 2 1955 1041 1048
3. A. Kornbluth, D.B. Sachar Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee Am J Gastroenterol 105 2010 501 523 quiz 524
4. S.P.L. Travis, E.F. Stange, M. Lémann European evidence-based consensus on the management of ulcerative colitis: current management J Crohns Colitis 2 2008 24 62
5. G.R. Lichtenstein, M.T. Abreu, R. Cohen American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease Gastroenterology 130 2006 940 987
6. J.D. Lewis, J.M. Gelfand, A.B. Troxel Immunosuppressant medications and mortality in inflammatory bowel disease Am J Gastroenterol 103 2008 1428 1435
7. S.C. Truelove Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium A report on a controlled therapeutic trial BMJ 2 1958 1072 1077
8. S.B. Hanauer, M. Robinson, R. Pruitt Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study U.S. Budesonide enema study group Gastroenterology 115 1998 525 532
9. R. Brattsand Overview of newer glucocorticosteroid preparations for inflammatory bowel disease Can J Gastroenterol 4 1990 407 414
10. S. Edsbacker, P. Larsson, P. Wollmer Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules Eur J Gastroenterol Hepatol 14 2002 1357 1362
11. S. Edsbacker, B. Bengtsson, P. Larsson A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules Aliment Pharmacol Ther 17 2003 525 536
12. G.R. Greenberg, B.G. Feagan, F. Martin Oral budesonide for active Crohn's disease Canadian Inflammatory Bowel Disease Study Group N Engl J Med 331 1994 836 841
13. P. Rutgeerts, R. Lofberg, H. Malchow A comparison of budesonide with prednisolone for active Crohn's disease N Engl J Med 331 1994 842 845
14. M. Campieri, A. Ferguson, W. Doe Oral budesonide is as effective as oral prednisolone in active Crohn's disease The Global Budesonide Study Group Gut 41 1997 209 214
15. W.J. Tremaine, S.B. Hanauer, S. Katz Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States Am J Gastroenterol 97 2002 1748 1754
16. S. Bar-Meir, Y. Chowers, A. Lavy Budesonide versus prednisone in the treatment of active Crohn's disease The Israeli Budesonide Study Group Gastroenterology 115 1998 835 840
17. G.R. Greenberg, B.G. Feagan, F. Martin Oral budesonide as maintenance treatment for Crohn's disease: a placebo- controlled, dose-ranging study Canadian Inflammatory Bowel Disease Study Group Gastroenterology 110 1996 45 51
18. R. Lofberg, P. Rutgeerts, H. Malchow Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease A placebo controlled one year study Gut 39 1996 82 86
19. A. Ferguson, M. Campieri, W. Doe Oral budesonide as maintenance therapy in Crohn's disease - results of a 12-month study Global Budesonide Study Group Aliment Pharmacol Ther 12 1998 175 183
20. S. Hanauer, W.J. Sandborn, A. Persson Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial Aliment Pharmacol Ther 21 2005 363 371
21. R. Lofberg, A. Danielsson, O. Suhr Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis Gastroenterology 110 1996 1713 1718
22. M. Brunner, H. Vogelsang, R. Greinwald Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis Aliment Pharmacol Ther 22 2005 463 470
23. M. Brunner, S. Ziegler, A.F. Di Stefano Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation Br J Clin Pharmacol 61 2006 31 38
24. G.R. D'Haens, A. Kovacs, P. Vergauwe Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX(R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitis J Crohns Colitis 4 2010 153 160
25. L.R. Sutherland, F. Martin, S. Greer 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis Gastroenterology 92 1987 1894 1898
26. G. D'Haens, W.J. Sandborn, B.G. Feagan A review of activity indices and efficacy endponts for clinical trials of medical therapy in adults with ulcerative colitis Gastroenterology 132 2007 763 786
27. D. Rachmilewitz Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial BMJ 298 1989 82 86
28. M.A. Kamm, W.J. Sandborn, M. Gassull Once-daily high concentration MMX mesalamine in active ulcerative colitis Gastroenterology 132 2007 66 75
29. G.R. Lichtenstein, M.A. Kamm, P. Boddu Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis Clin Gastroenterol Hepatol 5 2007 95 102
30. S.B. Hanauer, W.J. Sandborn, C. Dallaire Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial Can J Gastroenterol 21 2007 827 834
31. P. Rutgeerts, W.J. Sandborn, B.G. Feagan Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
32. S.H. Saverymuttu, M. Camilleri, H. Rees Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion Gastroenterology 90 1986 1121 1128
33. W.J. Sandborn, S. Travis, S. Danese Budesonide-MMx® 9 mg for induction of remission of mild-to-moderate ulcerative colitis (UC): data from a multicenter, randomized, double-blind placebo-controlled study in Europe, Russia, Israel and Australia Gastroenterology 140 Suppl 1 2011 S-65
34. K.W. Schroeder, W.J. Tremaine, D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis A randomized study N Engl J Med 317 1987 1625 1629
35. C.A. Sninsky, D.H. Cort, F. Shanahan Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis A multicenter study Ann Intern Med 115 1991 350 355